As a large amount of research work has already been performed in the field of tumour immunotherapy in GBM without reaching major break-throughs62, it may be interesting to combine therapeutic strategies targeting the clock with immune therapies with the aim to improve the efficiency of stand-alone tumour immunotherapy. The gene discussed is CLOCK; the disease is glioblastoma.